Lv11
20 积分 2021-08-04 加入
Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy
1小时前
待确认
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
1个月前
已完结
Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer
1个月前
已完结
Options for Endocrine-Refractory, Hormone Receptor–Positive Breast Cancer: Which Target and When?
2个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
5个月前
已完结
A Small-Molecule PARP7 Inhibitor Triggers Antitumor Immunity
4年前
已关闭
皖公网安备34019202002308
